]>
IRCT20200918048751N1 IRCT 2020-10-30 Zanjan University of Medical Sciences The effect of memantine in improving cognitive deficits, quality of life and reducing the negative symptoms in schizophrenic patients. The effectiveness of memantine in improving cognitive deficits, quality of life and reducing the negative symptoms of schizophrenia patients 2020-11-10 anticipated 40 Complete https://irct.ir/trial/51069 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible individuals will be randomly assigned to two groups. For this purpose, first a random sequence will be created from the table of random numbers. Then the extracted even numbers will be assigned to the intervention group and the odd numbers will be assigned to the control group. This process will continue to reach the sample size, Blinding description: Participants and research physicians will not be aware of the distribution of the drug and placebo, which are similar in color, size, shape, and odor to the original drug. To hide the drugs and placebo will be placed in a sealed matte envelope numbered in a row. Envelopes will be prepared by a non-research person. 3 Schizophrenia. Intervention 1: Intervention group: In addition to the routine treatment of schizophrenia (which includes one of the three antipsychotic drugs: clozapine, risperidone, olanzapine), Sobhan Company Memantine will be prescribed for three months. For this purpose, treatment with 5 mg memantine will be started and 5 mg weekly will be increased to 20 mg, then the 20 mg dose will be continued for two months. Intervention 2: Control group: In addition to routine treatment, the control group will receive a placebo. Routine treatment that includes one of three antipsychotic drugs: clozapine, risperidone, olanzapine. The follow-up period in the present study is 12 weeks. No - There is not a plan to make this available Justification or reason for not sharing IPD is Due to the dissatisfaction of the participants, a decision was made not to publish
public Joz Qanbari Reyhaneh
Shahid Dr. Beheshti Educational, Therapeutic and Psychiatric Center., Ark Square
Zanjan Iran (Islamic Republic of) 4513615788 +98 24 3354 2403 reyhane.jozghanbari@gmail.com Zanjan University of Medical Sciences scientific Armani kian Alireza
Deputy of Treatment., third floor., Bustan 2 .,University of Medical Sciences ., above Ayatollah Hospital ., Gavazang Road
Zanjan Iran (Islamic Republic of) 4513956111 +98 24 3301 8000 dr.armmami@gmail.com Zanjan University of Medical Sciences Iran (Islamic Republic of) Having diagnostic criteria (DSM-5) for patients with schizophrenia and at least two years after diagnosis Age 18 to 50 years Receive a fixed dose of antipsychotic for at least 8 weeks and for 4 weeks before enrollment Continue treatment with at least one antipsychotic drug during the study 18 years 50 years Both Outstanding neurological or organic disease in clinical and laboratory studies Existence of another axis-based diagnosis (DSM-5) Coexistence with mental retardation Drug addiction or abuse (except nicotine and caffeine) Inability to communicate High risk of suicide Receive ECT in the last two weeks History of memantine sensitivity Having kidney disease Pregnancy and lactation Do not use safe contraception in women F20.9 Schizophrenia, unspecified Treatment - Drugs Treatment - Drugs Intervention group: In addition to the routine treatment of schizophrenia (which includes one of the three antipsychotic drugs: clozapine, risperidone, olanzapine), Sobhan Company Memantine will be prescribed for three months. For this purpose, treatment with 5 mg memantine will be started and 5 mg weekly will be increased to 20 mg, then the 20 mg dose will be continued for two months. Control group: In addition to routine treatment, the control group will receive a placebo. Routine treatment that includes one of three antipsychotic drugs: clozapine, risperidone, olanzapine. The follow-up period in the present study is 12 weeks. Attention of schizophrenic patients. Timepoint: In two time periods before starting the drug and 12 weeks after starting the drug. Method of measurement: Strop computer test. Executive performance. Timepoint: In two time periods before starting the drug and 12 weeks after starting the drug. Method of measurement: London Tower Computer Test. Processing speed. Timepoint: In two time periods before starting the drug and 12 weeks after starting the drug. Method of measurement: Strop computer test. Negative symptoms. Timepoint: In the three time periods before, 8 and 12 weeks after the start of the intervention. Method of measurement: Negative Symptoms Assessment Scale. The quality of life. Timepoint: Three time periods before, 8 and 12 weeks after the start of the intervention. Method of measurement: Specific quality of life questionnaire for schizophrenic patients. Zanjan University of Medical Sciences Approved 2020-08-15 Ethics committee of zanjan University of Medical Sciences Therapeutic and Psychiatric Center, Ark Square, Shahid Dr. Beheshti Educational Zanjan Zanjan Iran (Islamic Republic of)